Answer
Aprocitentan inhibits OAT3 in vitro and may increase plasma concentrations of methotrexate, an OAT3 substrate with a narrow therapeutic index; a clinically relevant interaction cannot be excluded because no dedicated interaction study has been performed.
Sources for this answer
- JERAYGO 12.5 mg film-coated tabletsIdorsia Pharmaceuticals UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 1Document updated
Sources checked